Get started
Author

Eika Higashi

ORCID: 0009-0002-2093-8074
Observed ORCID: 0009-0002-2093-8074
OpenAlex ID: A5078491229
Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists
2015 · Toru Nemoto, Yusuke Iihara, et al. · Bioorganic & Medicinal Chemistry Letters · 20
Discovery of δ Opioid Receptor Full Inverse Agonists and Their Effects on Restraint Stress-Induced Cognitive Impairment in Mice
2019 · Shigeto Hirayama, Takashi Iwai, et al. · ACS Chemical Neuroscience · 15
Development of Novel δ Opioid Receptor Inverse Agonists without a Basic Nitrogen Atom and Their Antitussive Effects in Mice
2019 · Eika Higashi, Shigeto Hirayama, et al. · ACS Chemical Neuroscience · 8
C-Homomorphinan Derivatives as Lead Compounds to Obtain Safer and More Clinically Useful Analgesics
2017 · Kyoko Ishikawa, Fumika Karaki, et al. · Chemical and Pharmaceutical Bulletin · 6
PDF
Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors
2021 · Yuka Uenohara, Saori Tsumura, et al. · Bioorganic & Medicinal Chemistry · 3
PDF
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Data from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Works count: 36
Citation count: 52
H-index: 4
I10-index: 2
Year
Topic
Type